Dear Editor:

Intravenous high-dose vitamin C is a promising method for mitigating acute herpetic pain (AHP) and postherpetic neuralgia (PHN)[@B1][@B2][@B3]. We are interested in the research by Kim et al.[@B4] on the efficacy of intravenous vitamin C (5 g every second day for 3 times) on relieving AHP and decreasing the incidence of PHN. Although the incidence of PHN in the vitamin C group was significantly lower compared to that in the control group, no significant differences were noted in the intensity of AHP between the two groups. Therefore, Kim et al.[@B4] concluded that intravenous vitamin C was ineffective in relieving AHP.

In describing the rationale for choosing the dosage of intravenous vitamin C, Kim et al.[@B4] cited 3 references in which "effect of vitamin C has been reported at a dose of 2.5 g in PHN and at a dose of 7.5 g, 15 g in acute phase." Of these references regarding AHP, 1) Schencking et al.[@B2] reported total remission of the cutaneous lesions and AHP in 2 patients with shingles after intravenous vitamin C 15 g every second day for total doses of 60 and 90 g, respectively; 2) a prospective cohort study[@B3], in which shingles patients received intravenous infusions of vitamin C (7.5 g for 2 to 4 times per week, for approximately 2 weeks) in addition to standard treatment, concluded that vitamin C at an average total dose of 60 g effectively reduced AHP. In the research by Kim et al.[@B4], however, intravenous vitamin C in a total dose of 15 g was surprisingly low in view of the above-mentioned references. More importantly, there was no data on the efficacy of vitamin C greater than 15 g on AHP in that study. Kim et al.[@B4] concluded that intravenous vitamin C was ineffective in relieving AHP; however, effects of vitamin C have been demonstrated to be dose-dependent[@B5].

Recently, we had successful experience of relieving AHP by intravenous high-dose vitamin C (5 g/d) in one female. On the third day of intravenous vitamin C therapy (for a cumulative dose of 15 g), AHP was not relieved at all. This finding was compatible with that of Kim et al.[@B4] Further treatment with intravenous vitamin C, however, brought about obvious reduction of pain intensity, frequency and duration of each pain episode in one week. The patient received a total of 35 g of intravenous vitamin C. In conclusion, while the efficacy of high-dose vitamin C on AHP is not yet conclusive, the conclusion by Kim et al.[@B4] that intravenous ascorbic acid did not relieve AHP effectively was unjustified. Our case supported the valuable finding by Kim et al.[@B4] that intravenous vitamin C in a total dose of 15 g was not enough for relieving AHP. Nonetheless, a more proper conclusion is that a total dose 15 g of intravenous ascorbic acid did not effectively relieve AHP.
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